PedAM
Pediatric Disease Annotations & Medicines
| diffuse large b-cell lymphoma | ||||
| Disease ID | 242 |
|---|---|
| Disease | diffuse large b-cell lymphoma |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:11) C2364133 | infection C1963091 | diarrhea C1535939 | pneumocystis jiroveci pneumonia C0877417 | cytomegalovirus enterocolitis C0349412 | refractory shock C0334634 | mantle cell lymphoma C0040038 | thromboembolism C0037140 | b virus infection C0027697 | nephritis C0018378 | guillain-barre syndrome C0008626 | chromosomal abnormality |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:4) C0009450 | infection | 5 C0037140 | b virus infection | 2 C0032305 | pneumocystis jiroveci pneumonia | 2 C0040038 | thromboembolism | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:73) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs1045642 | 23829278 | 5243 | ABCB1 | umls:C0079744 | BeFree | The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2). | 0.121628651 | 2014 | ABCB1 | 7 | 87509329 | A | T,G |
| rs1045642 | 23829278 | 4524 | MTHFR | umls:C0079744 | BeFree | The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2). | 0.013192369 | 2014 | ABCB1 | 7 | 87509329 | A | T,G |
| rs11045879 | 23829278 | 5243 | ABCB1 | umls:C0079744 | BeFree | The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2). | 0.121628651 | 2014 | SLCO1B1 | 12 | 21229685 | T | C |
| rs11045879 | 23829278 | 4524 | MTHFR | umls:C0079744 | BeFree | The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2). | 0.013192369 | 2014 | SLCO1B1 | 12 | 21229685 | T | C |
| rs113488022 | 22575864 | 4893 | NRAS | umls:C0079744 | BeFree | Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H). | 0.000542884 | 2012 | BRAF | 7 | 140753336 | A | T,G,C |
| rs113488022 | 22575864 | 673 | BRAF | umls:C0079744 | BeFree | Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H). | 0.000271442 | 2012 | BRAF | 7 | 140753336 | A | T,G,C |
| rs11554290 | 9139869 | 4893 | NRAS | umls:C0079744 | BeFree | Altogether, one diffuse large B-cell lymphoma and one B-cell chronic lymphocytic leukemia (B-CLL) harbored a mutation (G12S and G12A, respectively) in the K-ras gene, and one B-CLL harbored a mutation (Q61R) in the N-ras gene. | 0.000542884 | 1997 | NRAS | 1 | 114713908 | T | G,C,A |
| rs121913237 | 9139869 | 4893 | NRAS | umls:C0079744 | BeFree | Altogether, one diffuse large B-cell lymphoma and one B-cell chronic lymphocytic leukemia (B-CLL) harbored a mutation (G12S and G12A, respectively) in the K-ras gene, and one B-CLL harbored a mutation (Q61R) in the N-ras gene. | 0.000542884 | 1997 | NRAS | 1 | 114716126 | C | T,G,A |
| rs121913250 | 9139869 | 4893 | NRAS | umls:C0079744 | BeFree | Altogether, one diffuse large B-cell lymphoma and one B-cell chronic lymphocytic leukemia (B-CLL) harbored a mutation (G12S and G12A, respectively) in the K-ras gene, and one B-CLL harbored a mutation (Q61R) in the N-ras gene. | 0.000542884 | 1997 | NRAS | 1 | 114716127 | C | T,G,A |
| rs121913254 | 22575864 | 673 | BRAF | umls:C0079744 | BeFree | Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H). | 0.000271442 | 2012 | NRAS | 1 | 114713909 | G | T,C |
| rs121913254 | 22575864 | 4893 | NRAS | umls:C0079744 | BeFree | Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H). | 0.000542884 | 2012 | NRAS | 1 | 114713909 | G | T,C |
| rs121913255 | 22575864 | 673 | BRAF | umls:C0079744 | BeFree | Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H). | 0.000271442 | 2012 | NRAS | 1 | 114713907 | T | A |
| rs121913255 | 22575864 | 4893 | NRAS | umls:C0079744 | BeFree | Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H). | 0.000542884 | 2012 | NRAS | 1 | 114713907 | T | A |
| rs121913338 | 22575864 | 4893 | NRAS | umls:C0079744 | BeFree | Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H). | 0.000542884 | 2012 | BRAF | 7 | 140753354 | T | C,A |
| rs121913338 | 22575864 | 673 | BRAF | umls:C0079744 | BeFree | Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H). | 0.000271442 | 2012 | BRAF | 7 | 140753354 | T | C,A |
| rs121913365 | 22575864 | 4893 | NRAS | umls:C0079744 | BeFree | Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H). | 0.000542884 | 2012 | BRAF | 7 | 140753332 | T | G |
| rs121913365 | 22575864 | 673 | BRAF | umls:C0079744 | BeFree | Mutations of the BRAF gene were identified in six (24%) diffuse large B-cell lymphomas (D594G in three germinal center diffuse large B-cell lymphomas, K601N in two germinal center diffuse large B-cell lymphomas, and V600E in one non-germinal center diffuse large B-cell lymphoma) and of the NRAS gene in two (8%) non-germinal center diffuse large B-cell lymphomas (Q61K and Q61H). | 0.000271442 | 2012 | BRAF | 7 | 140753332 | T | G |
| rs12711521 | 23055202 | 4155 | MBP | umls:C0079744 | BeFree | A SNP-based analysis showed that MBP rs8094402 was associated with decreased risks of overall NHL (allele risk OR = 0.72, P-trend = 0.0018), DLBCL (allele risk OR = 0.72, P-trend = 0.036), and FL (allele risk OR = 0.67, P-trend = 0.021), while MASP2 rs12711521 was associated with a decreased risk of DLBCL (allele risk OR = 0.57, P-trend = 0.0042). | 0.000271442 | 2013 | MASP2 | 1 | 11030859 | C | A |
| rs12711521 | 23055202 | 10747 | MASP2 | umls:C0079744 | BeFree | A SNP-based analysis showed that MBP rs8094402 was associated with decreased risks of overall NHL (allele risk OR = 0.72, P-trend = 0.0018), DLBCL (allele risk OR = 0.72, P-trend = 0.036), and FL (allele risk OR = 0.67, P-trend = 0.021), while MASP2 rs12711521 was associated with a decreased risk of DLBCL (allele risk OR = 0.57, P-trend = 0.0042). | 0.000271442 | 2013 | MASP2 | 1 | 11030859 | C | A |
| rs12917 | 22430443 | 4255 | MGMT | umls:C0079744 | BeFree | After stratification by major NHL histological subtypes, MGMT (rs12917) modified the association between chlorinated solvents and the risk of diffuse large B-cell lymphoma (Pfor interaction=0.0027) and follicular lymphoma (Pfor interaction=0.0024). | 0.005081451 | 2012 | MGMT | 10 | 129708019 | C | T |
| rs13181 | 23619945 | 2068 | ERCC2 | umls:C0079744 | BeFree | A significant interaction with BMI was only observed for WRN (rs1801195; P = 0.004) for T-cell lymphoma and ERCC2 (rs13181; P = 0.002) for diffuse large B-cell lymphoma. | 0.005819831 | 2013 | ERCC2;KLC3 | 19 | 45351661 | T | A,G |
| rs13181 | 23619945 | 7486 | WRN | umls:C0079744 | BeFree | A significant interaction with BMI was only observed for WRN (rs1801195; P = 0.004) for T-cell lymphoma and ERCC2 (rs13181; P = 0.002) for diffuse large B-cell lymphoma. | 0.002909916 | 2013 | ERCC2;KLC3 | 19 | 45351661 | T | A,G |
| rs13255292 | 25261932 | 5820 | PVT1 | umls:C0079744 | GWASCAT | Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. | 0.12 | 2014 | PVT1 | 8 | 128064327 | C | T |
| rs1625895 | 25430047 | 7157 | TP53 | umls:C0079744 | BeFree | The G/G genotype of the TP53 rs1625895 polymorphism was shown to be associated with a high probability of R-CHOP therapy failure in DLBCL patients according to the probability of remission as well as 5-year overall and relapse-free survivals. | 0.026612573 | 2014 | TP53 | 17 | 7674797 | T | G,C |
| rs1625895 | 25430047 | 1649 | DDIT3 | umls:C0079744 | BeFree | The G/G genotype of the TP53 rs1625895 polymorphism was shown to be associated with a high probability of R-CHOP therapy failure in DLBCL patients according to the probability of remission as well as 5-year overall and relapse-free survivals. | 0.014114977 | 2014 | TP53 | 17 | 7674797 | T | G,C |
| rs172378 | 21883784 | 712 | C1QA | umls:C0079744 | BeFree | The influence of C1qA-A276G polymorphisms in DLBCL, and the impact of both polymorphisms on susceptibility to LON and outcome were also examined. | 0.002909916 | 2012 | C1QA | 1 | 22638945 | A | G |
| rs1799782 | 17666372 | 7515 | XRCC1 | umls:C0079744 | BeFree | In addition, the XRCC1 Arg194Trp polymorphism was associated with decreased NHL risk (Arg/Trp vs. Arg/Arg, OR: 0.72; 95% CI: 0.49-1.07; Trp/Trp vs. Arg/Arg, OR: 0.45; 95% CI: 0.10-1.99; p trend: 0.059), mainly in diffuse large B-cell lymphoma. | 0.005276948 | 2007 | XRCC1 | 19 | 43553422 | G | A |
| rs1800629 | 23391141 | 7124 | TNF | umls:C0079744 | BeFree | Variants in TNFα (rs1800629) (GG vs. AG/AA, p < 0.001) and LTA (rs909253) (AA vs. AG/GG, p = 0.02) and deletions in GSTM1 and GSTT1 (undeleted vs. deleted, p = 0.01 and p = 0.01, respectively) were associated with increased susceptibility of developing DLBCL. | 0.008262808 | 2014 | TNF | 6 | 31575254 | G | A |
| rs1800629 | 23391141 | 2944 | GSTM1 | umls:C0079744 | BeFree | Variants in TNFα (rs1800629) (GG vs. AG/AA, p < 0.001) and LTA (rs909253) (AA vs. AG/GG, p = 0.02) and deletions in GSTM1 and GSTT1 (undeleted vs. deleted, p = 0.01 and p = 0.01, respectively) were associated with increased susceptibility of developing DLBCL. | 0.00554839 | 2014 | TNF | 6 | 31575254 | G | A |
| rs1800629 | 23640160 | 7124 | TNF | umls:C0079744 | BeFree | TNF rs1800629, which was genotyped in only two of our studies, was also associated with B cell lymphoma (per-allele OR = 0.77, 95 % CI 0.64-0.91; p trend = 0.003), specifically DLBCL (per-allele OR = 0.69, 95 % CI 0.55-0.86; p trend = 0.001). | 0.008262808 | 2013 | TNF | 6 | 31575254 | G | A |
| rs1800629 | 23391141 | 2952 | GSTT1 | umls:C0079744 | BeFree | Variants in TNFα (rs1800629) (GG vs. AG/AA, p < 0.001) and LTA (rs909253) (AA vs. AG/GG, p = 0.02) and deletions in GSTM1 and GSTT1 (undeleted vs. deleted, p = 0.01 and p = 0.01, respectively) were associated with increased susceptibility of developing DLBCL. | 0.00554839 | 2014 | TNF | 6 | 31575254 | G | A |
| rs1800890 | 20087644 | 3586 | IL10 | umls:C0079744 | BeFree | IL10 rs1800890 was associated with risk of diffuse large B-cell lymphoma (OR 1.41, CI 1.08-1.85 for minor allele homozygosity) and mantle cell lymphoma (OR 1.77, CI 1.04-3.00). | 0.01617823 | 2010 | IL10 | 1 | 206776020 | A | T |
| rs1800890 | 22609637 | 3586 | IL10 | umls:C0079744 | BeFree | Compared with women who were never occupationally exposed to any organic solvents, women who were exposed to organic solvents at least once had a significantly increased risk for diffuse large B-cell lymphoma if they carried the IL10 (rs1800890) TT genotype (odds ratio=3.31, 95% confidence interval: 1.80-6.08), but not if they carried the AT/AA genotype (odds ratio=1.14, 95% confidence interval: 0.72-1.79). | 0.01617823 | 2013 | IL10 | 1 | 206776020 | A | T |
| rs1800896 | 23640160 | 3586 | IL10 | umls:C0079744 | BeFree | IL10 rs1800896 was associated with B cell lymphoma [per-allele odds ratio (OR) = 1.25, 95 % confidence interval (CI) 1.08-1.45; p trend = 0.003], specifically diffuse large B cell lymphoma (DLBCL) (per-allele OR = 1.29, 95 % CI 1.08-1.53; p trend = 0.004), as well as T cell lymphoma (per-allele OR = 1.44, 95 % CI 1.13-1.82; p trend = 0.003). | 0.01617823 | 2013 | IL10 | 1 | 206773552 | T | C |
| rs1801131 | 23829278 | 4524 | MTHFR | umls:C0079744 | BeFree | The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2). | 0.013192369 | 2014 | MTHFR | 1 | 11794419 | T | G |
| rs1801131 | 23829278 | 5243 | ABCB1 | umls:C0079744 | BeFree | The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2). | 0.121628651 | 2014 | MTHFR | 1 | 11794419 | T | G |
| rs1801133 | 23829278 | 5243 | ABCB1 | umls:C0079744 | BeFree | The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2). | 0.121628651 | 2014 | MTHFR | 1 | 11796321 | G | A |
| rs1801133 | 23829278 | 4524 | MTHFR | umls:C0079744 | BeFree | The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2). | 0.013192369 | 2014 | MTHFR | 1 | 11796321 | G | A |
| rs1801195 | 23619945 | 2068 | ERCC2 | umls:C0079744 | BeFree | A significant interaction with BMI was only observed for WRN (rs1801195; P = 0.004) for T-cell lymphoma and ERCC2 (rs13181; P = 0.002) for diffuse large B-cell lymphoma. | 0.005819831 | 2013 | WRN | 8 | 31141764 | G | T |
| rs1801195 | 23619945 | 7486 | WRN | umls:C0079744 | BeFree | A significant interaction with BMI was only observed for WRN (rs1801195; P = 0.004) for T-cell lymphoma and ERCC2 (rs13181; P = 0.002) for diffuse large B-cell lymphoma. | 0.002909916 | 2013 | WRN | 8 | 31141764 | G | T |
| rs1805010 | 19515749 | 3566 | IL4R | umls:C0079744 | GAD | [Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial.] | 0.005005506 | 2009 | IL4R | 16 | 27344882 | A | C,G,T |
| rs1880030 | 19336552 | 605 | BCL7A | umls:C0079744 | BeFree | Variants in BCL7A were strongly related to diffuse large B-cell lymphoma only, particularly rs1880030 (OR(AG), 1.34; 95% CI, 1.08-1.68; OR(AA), 1.60; 95% CI, 1.22-2.08; P(trend) = 0.0004). | 0.002638474 | 2009 | BCL7A | 12 | 122046634 | G | A |
| rs2032582 | 23829278 | 4524 | MTHFR | umls:C0079744 | BeFree | The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2). | 0.013192369 | 2014 | ABCB1 | 7 | 87531302 | A | T,C |
| rs2032582 | 23829278 | 5243 | ABCB1 | umls:C0079744 | BeFree | The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2). | 0.121628651 | 2014 | ABCB1 | 7 | 87531302 | A | T,C |
| rs2231142 | 19032367 | 9429 | ABCG2 | umls:C0079744 | BeFree | ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy. | 0.123452799 | 2008 | ABCG2 | 4 | 88131171 | G | T |
| rs2234922 | 21228414 | 2052 | EPHX1 | umls:C0079744 | BeFree | The weak, nonsignificant overall association between benzene and diffuse large B-cell lymphoma (OR = 1.29, 95% CI: 0.84, 1.98) was increased among women AA for rs2234922 in the microsomal epoxide hydrolase gene, EPHX1 (OR = 1.77, 95% CI: 1.06, 2.97; P(interaction) = 0.06). | 0.000271442 | 2011 | EPHX1 | 1 | 225838705 | A | G,T |
| rs2523607 | 25261932 | 102465537 | MIR6891 | umls:C0079744 | GWASCAT | Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. | 0.12 | 2014 | HLA-B;MIR6891 | 6 | 31355013 | T | A |
| rs2523607 | 25261932 | 3106 | HLA-B | umls:C0079744 | GWASCAT | Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. | 0.12 | 2014 | HLA-B;MIR6891 | 6 | 31355013 | T | A |
| rs2681416 | 25261932 | 942 | CD86 | umls:C0079744 | GWASCAT | Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. | 0.12 | 2014 | CD86 | 3 | 122098766 | G | A |
| rs2910164 | 25370733 | 406938 | MIR146A | umls:C0079744 | BeFree | MicroRNA-146a rs2910164 polymorphism and the risk of diffuse large B cell lymphoma in the Chinese Han population. | 0.000271442 | 2014 | LOC285628;MIR146A | 5 | 160485411 | C | G |
| rs3813729 | 22170086 | 51279 | C1RL | umls:C0079744 | BeFree | A SNP-based analysis showed that a C>T base substitution for C1RL rs3813729 (odds ratio (OR)(CT) = 0.60, 95% confidence interval (CI) = 0.42-0.87, P(trend) = 0.0062) was associated with a decreased risk of overall NHL, as well as for DLBCL (OR(CT) = 0.39, 95% CI = 0.20-0.73; P(trend) = 0.0034). | 0.000271442 | 2012 | NA | NA | NA | NA | NA |
| rs386545546 | 17666372 | 7515 | XRCC1 | umls:C0079744 | BeFree | In addition, the XRCC1 Arg194Trp polymorphism was associated with decreased NHL risk (Arg/Trp vs. Arg/Arg, OR: 0.72; 95% CI: 0.49-1.07; Trp/Trp vs. Arg/Arg, OR: 0.45; 95% CI: 0.10-1.99; p trend: 0.059), mainly in diffuse large B-cell lymphoma. | 0.005276948 | 2007 | NA | NA | NA | NA | NA |
| rs387907272 | 25768255 | 4615 | MYD88 | umls:C0079744 | BeFree | Myd-88 L265P constitutive activating mutations are present in at least some cases of the diffuse large B-cell lymphoma form of vitreoretinal lymphoma. | 0.122171535 | 2015 | MYD88 | 3 | 38141150 | T | C |
| rs387907272 | 23178471 | 4615 | MYD88 | umls:C0079744 | BeFree | Heterozygous MYD88 L265P mutations were identified in 11 (9.2%) DLBCL cases, all of which were diagnosed as non-germinal-center B cell (non-GCB) DLBCL. | 0.122171535 | 2013 | MYD88 | 3 | 38141150 | T | C |
| rs387907272 | 23380077 | 4615 | MYD88 | umls:C0079744 | BeFree | MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. | 0.122171535 | 2013 | MYD88 | 3 | 38141150 | T | C |
| rs3957357 | 19448608 | 1535 | CYBA | umls:C0079744 | BeFree | Overall, host SNPs affecting doxorubicin pharmacodynamics (CYBA rs4673) and alkylator detoxification (GSTA1 rs3957357) may predict outcome in R-CHOP21-treated DLBCL. | 0.000271442 | 2009 | GSTA1 | 6 | 52803889 | A | G |
| rs3957357 | 19448608 | 2938 | GSTA1 | umls:C0079744 | BeFree | Overall, host SNPs affecting doxorubicin pharmacodynamics (CYBA rs4673) and alkylator detoxification (GSTA1 rs3957357) may predict outcome in R-CHOP21-treated DLBCL. | 0.000271442 | 2009 | GSTA1 | 6 | 52803889 | A | G |
| rs4149056 | 23829278 | 5243 | ABCB1 | umls:C0079744 | BeFree | The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2). | 0.121628651 | 2014 | SLCO1B1 | 12 | 21178615 | T | C |
| rs4149056 | 23829278 | 4524 | MTHFR | umls:C0079744 | BeFree | The present study evaluated the impact of single gene polymorphisms (SNPs: rs1801133 and rs1801131 in the MTHFR gene; rs4149056 and rs11045879 in the SLC01B1 gene; and rs2032582 and rs1045642 in the ABCB1 transporter gene) on MTX blood levels and toxicity in samples from 69 patients with diffuse large-B-cell lymphoma (DLBCL) treated with high dose intravenous (HD IV) MTX, > 2 g/m(2). | 0.013192369 | 2014 | SLCO1B1 | 12 | 21178615 | T | C |
| rs4673 | 19448608 | 2938 | GSTA1 | umls:C0079744 | BeFree | Overall, host SNPs affecting doxorubicin pharmacodynamics (CYBA rs4673) and alkylator detoxification (GSTA1 rs3957357) may predict outcome in R-CHOP21-treated DLBCL. | 0.000271442 | 2009 | CYBA | 16 | 88646828 | A | G |
| rs4673 | 19448608 | 1535 | CYBA | umls:C0079744 | BeFree | Overall, host SNPs affecting doxorubicin pharmacodynamics (CYBA rs4673) and alkylator detoxification (GSTA1 rs3957357) may predict outcome in R-CHOP21-treated DLBCL. | 0.000271442 | 2009 | CYBA | 16 | 88646828 | A | G |
| rs601341 | 17169801 | 4361 | MRE11A | umls:C0079744 | BeFree | A protective effect against follicular lymphoma was seen for the MRE11 rs601341 variant, the homozygous T allele being associated with an odds ratio (OR) of 0.50, 95% confidence interval (95% CI) 0.26 - 0.97, while a protective effect was seen for the MRE11 haplotype GCTCA (OR 0.72, 95% CI 0.53 - 0.97) for diffuse large B-cell lymphoma. | 0.000271442 | 2006 | MRE11A | 11 | 94434611 | G | A |
| rs6773854 | 23749188 | 51750 | RTEL1 | umls:C0079744 | BeFree | We identified a new susceptibility locus, rs6773854, located between BCL6 (encoding B cell lymphoma protein 6) and LPP (encoding lipoma preferred partner) on oncogene-rich chromosome 3q27 that was significantly associated with increased risk of B cell NHL (meta-analysis P = 3.36 × 10⁻¹³, per-allele odds ratio (OR) = 1.44) and with diffuse large B cell lymphoma (DLBCL) in particular (meta-analysis P = 1.14 × 10⁻¹¹, OR = 1.47). | 0.003257302 | 2013 | LOC105374265 | 3 | 187931631 | T | C |
| rs6773854 | 23749188 | 4026 | LPP | umls:C0079744 | BeFree | We identified a new susceptibility locus, rs6773854, located between BCL6 (encoding B cell lymphoma protein 6) and LPP (encoding lipoma preferred partner) on oncogene-rich chromosome 3q27 that was significantly associated with increased risk of B cell NHL (meta-analysis P = 3.36 × 10⁻¹³, per-allele odds ratio (OR) = 1.44) and with diffuse large B cell lymphoma (DLBCL) in particular (meta-analysis P = 1.14 × 10⁻¹¹, OR = 1.47). | 0.000271442 | 2013 | LOC105374265 | 3 | 187931631 | T | C |
| rs6773854 | 23749188 | 604 | BCL6 | umls:C0079744 | BeFree | We identified a new susceptibility locus, rs6773854, located between BCL6 (encoding B cell lymphoma protein 6) and LPP (encoding lipoma preferred partner) on oncogene-rich chromosome 3q27 that was significantly associated with increased risk of B cell NHL (meta-analysis P = 3.36 × 10⁻¹³, per-allele odds ratio (OR) = 1.44) and with diffuse large B cell lymphoma (DLBCL) in particular (meta-analysis P = 1.14 × 10⁻¹¹, OR = 1.47). | 0.033311405 | 2013 | LOC105374265 | 3 | 187931631 | T | C |
| rs7097 | 21471979 | 51082 | POLR1D | umls:C0079744 | GAD | [Common variants on 14q32 and 13q12 are associated with DLBCL susceptibility.] | 0.002367032 | 2011 | POLR1D | 13 | 27623299 | C | T |
| rs751837 | 21471979 | 9578 | CDC42BPB | umls:C0079744 | GAD | [Common variants on 14q32 and 13q12 are associated with DLBCL susceptibility.] | 0.002367032 | 2011 | CDC42BPB | 14 | 103018488 | T | C |
| rs79464052 | 25261932 | 64411 | ARAP3 | umls:C0079744 | GWASCAT | Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. | 0.12 | 2014 | ARAP3 | 5 | 141655607 | G | C |
| rs8094402 | 23055202 | 4155 | MBP | umls:C0079744 | BeFree | A SNP-based analysis showed that MBP rs8094402 was associated with decreased risks of overall NHL (allele risk OR = 0.72, P-trend = 0.0018), DLBCL (allele risk OR = 0.72, P-trend = 0.036), and FL (allele risk OR = 0.67, P-trend = 0.021), while MASP2 rs12711521 was associated with a decreased risk of DLBCL (allele risk OR = 0.57, P-trend = 0.0042). | 0.000271442 | 2013 | MBP | 18 | 76995493 | A | G |
| rs8094402 | 23055202 | 10747 | MASP2 | umls:C0079744 | BeFree | A SNP-based analysis showed that MBP rs8094402 was associated with decreased risks of overall NHL (allele risk OR = 0.72, P-trend = 0.0018), DLBCL (allele risk OR = 0.72, P-trend = 0.036), and FL (allele risk OR = 0.67, P-trend = 0.021), while MASP2 rs12711521 was associated with a decreased risk of DLBCL (allele risk OR = 0.57, P-trend = 0.0042). | 0.000271442 | 2013 | MBP | 18 | 76995493 | A | G |
| rs909253 | 23391141 | 7124 | TNF | umls:C0079744 | BeFree | Variants in TNFα (rs1800629) (GG vs. AG/AA, p < 0.001) and LTA (rs909253) (AA vs. AG/GG, p = 0.02) and deletions in GSTM1 and GSTT1 (undeleted vs. deleted, p = 0.01 and p = 0.01, respectively) were associated with increased susceptibility of developing DLBCL. | 0.008262808 | 2014 | LTA;LOC100287329 | 6 | 31572536 | A | G |
| rs909253 | 23391141 | 2952 | GSTT1 | umls:C0079744 | BeFree | Variants in TNFα (rs1800629) (GG vs. AG/AA, p < 0.001) and LTA (rs909253) (AA vs. AG/GG, p = 0.02) and deletions in GSTM1 and GSTT1 (undeleted vs. deleted, p = 0.01 and p = 0.01, respectively) were associated with increased susceptibility of developing DLBCL. | 0.00554839 | 2014 | LTA;LOC100287329 | 6 | 31572536 | A | G |
| rs909253 | 23391141 | 2944 | GSTM1 | umls:C0079744 | BeFree | Variants in TNFα (rs1800629) (GG vs. AG/AA, p < 0.001) and LTA (rs909253) (AA vs. AG/GG, p = 0.02) and deletions in GSTM1 and GSTT1 (undeleted vs. deleted, p = 0.01 and p = 0.01, respectively) were associated with increased susceptibility of developing DLBCL. | 0.00554839 | 2014 | LTA;LOC100287329 | 6 | 31572536 | A | G |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:11) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0079744 | carmustine | D002330 | 154-93-8 | lymphoma, large b-cell, diffuse | MESH:D016403 | therapeutic | 15286697 | ||
| C0079744 | chlorambucil | D002699 | 305-03-3 | lymphoma, large b-cell, diffuse | MESH:D016403 | marker/mechanism | 16432856 | ||
| C0079744 | cladribine | D017338 | 4291-63-8 | lymphoma, large b-cell, diffuse | MESH:D016403 | marker/mechanism | 16432856 | ||
| C0079744 | cyclophosphamide | D003520 | 50-18-0 | lymphoma, large b-cell, diffuse | MESH:D016403 | therapeutic | 10578547 | ||
| C0079744 | cisplatin | D002945 | 15663-27-1 | lymphoma, large b-cell, diffuse | MESH:D016403 | therapeutic | 25039915 | ||
| C0079744 | everolimus | D000068338 | - | lymphoma, large b-cell, diffuse | MESH:D016403 | therapeutic | 16856892 | ||
| C0079744 | leucovorin | D002955 | 1958/5/9 | lymphoma, large b-cell, diffuse | MESH:D016403 | therapeutic | 7857106 | ||
| C0079744 | gemcitabine | C056507 | 103882-84-4 | lymphoma, large b-cell, diffuse | MESH:D016403 | therapeutic | 25039915 | ||
| C0079744 | methotrexate | D008727 | 1959/5/2 | lymphoma, large b-cell, diffuse | MESH:D016403 | therapeutic | 10090607 | ||
| C0079744 | sirolimus | D020123 | 53123-88-9 | lymphoma, large b-cell, diffuse | MESH:D016403 | therapeutic | 16856892 | ||
| C0079744 | vincristine | D014750 | - | lymphoma, large b-cell, diffuse | MESH:D016403 | therapeutic | 10578547 | ||
FDA approved drug and dosage information(Total Drugs:0) | |
|---|---|
| (Waiting for update.) | |
FDA labeling changes(Total Drugs:0) | |
|---|---|
| (Waiting for update.) | |